EMA's CHMP Declines to OK Santhera's Raxone for Blindness

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has had another Glybera moment, turning down the rare disease drug Raxone (idebenone) by a narrow majority, despite the rapporteurs on an expert committee recommending approval of the drug, which treats a hereditary cause of blindness.

To continue reading subscribe now to BioWorld Asia (formerly International)